CollinBlakelyMDPh.D.

Oncology • San Francisco, CA

Hematologic Oncology, Thoracic Cancer

Clinical Instructor, Internal Medicine, UCSF School of Medicine

Join to view full profile

Dr. Blakely is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Blakely's full profile

Already have an account?

Office
505 Parnassus Ave
San Francisco, CA 94143
Phone+1 415-885-7276

Fax+1 415-353-9615
Is this information wrong?

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2009 - 2011
University of Pennsylvania Health SystemResidency, Internal Medicine, 2007 - 2009
Perelman School of Medicine at the University of PennsylvaniaClass of 2007

Certifications & Licensure

CA State Medical License 2009 - 2026
PA State Medical License 2007 - 2009
American Board of Internal Medicine Medical Oncology

Clinical Trials

Rociletinib (CO-1686) USA Expanded Access Program
No longer available
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2017 Sep 09
Terminated
Phase 1
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery Start of enrollment: 2018 Jul 31
Active, not recruiting
Phase 2
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer Start of enrollment: 2019 Nov 12
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Targeting MEK in non-small cell lung cancer.
Lara, M., Blakely, C., Riess, J.> ;Current Problems in Cancer. 2024 Feb 9
21 citations
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC.
Marcelo V Negrao, Haniel A Araujo, Giuseppe Lamberti, Alissa J Cooper, Neal S Akhave, Teng Zhou, Lukas Delasos, J Kevin Hicks, Mihaela Aldea, Gabriele Minuti, Jacobi H...> ;Cancer Discovery. 2023 Jul 7
2 citations
Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.
Michael P Douglas, Meera V Ragavan, Cheng Chen, Anika Kumar, Stacy W Gray, Collin M Blakely, Kathryn A Phillips> ;Journal of the National Comprehensive Cancer Network. 2023 Jun 1
6 citations
Osimertinib in NSCLC With Atypical-Activating Mutations: A Retrospective Multicenter Study.
Jingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, Laura Huppert, Julia K Rotow, Hatim Husain, Susan Stewart, Rosemary Cobb, Heather A Wakelee, Collin M Blakely, M...> ;JTO Clinical and Research Reports. 2023 Mar 1
6 citations
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
Kai He, David Berz, Shirish M Gadgeel, Wade T Iams, Debora S Bruno, Collin M Blakely, Alexander I Spira, Manish R Patel, David M Waterhouse, Donald A Richards, Anthony...> ;Journal of Thoracic Oncology. 2023 Jul 1
8 citations
CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.
Dong-Wan Kim, Sang-We Kim, D Ross Camidge, Catherine A Shu, Kristen A Marrone, Xiuning Le, Collin M Blakely, Keunchil Park, Gee-Chen Chang, Sandip Pravin Patel, Gozde ...> ;Journal of Thoracic Oncology. 2023 May 1
6 citations
Primary endpoints to assess the efficacy of novel therapeutic approaches in epidermal growth factor receptor-mutated, surgically resectable non-small cell lung cancer:...
Collin M Blakely, Walter Weder, Lukas Bubendorf, Jianxing He, Margarita Majem, Yu Shyr, Jamie E Chaft> ;Lung Cancer. 2023 Mar 1
1 citations
Phase 1 Study of Ceritinib Combined With Trametinib in Patients With Advanced ALK- or ROS1-Positive NSCLC.
Matthew S Lara, Matthew A Gubens, Bianca Bacaltos, Lea Daran, Steffany L Lim, Tianhong Li, David R Gandara, Trever G Bivona, Jonathan W Riess, Collin M Blakely> ;JTO Clinical and Research Reports. 2022 Dec 1
27 citations
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.
Ashish Noronha, Nishanth Belugali Nataraj, Joo Sang Lee, Benny Zhitomirsky, Yaara Oren, Sara Oster, Moshit Lindzen, Saptaparna Mukherjee, Rainer Will, Soma Ghosh, Artu...> ;Cancer Discovery. 2022 Nov 2
13 citations
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.
Moiez Ali, Min Lu, Hazel Xiaohui Ang, Ryan S Soderquist, Christine E Eyler, Haley M Hutchinson, Carolyn Glass, Christopher F Bassil, Omar M Lopez, D Lucas Kerr, Christ...> ;Science Translational Medicine. 2022 Mar 30
2 citations
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Dora Barbosa Rabago, Collin M. Blakely, Franziska Haderk, Trever G. Bivona> ;Journal of Visualized Experiments. 2021 Nov 22
7 citations
Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study.
Melisa L. Wong, Ying Shi, Alexander K. Smith, Christine Miaskowski, W. John Boscardin, Harvey J. Cohen, Vivian Lam, Melissa Mazor, Lia Metzger, Carolyn J Presley, Gran...> ;Journal of the American Geriatrics Society. 2021 Oct 5
6 citations
Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence...
Gavitt A. Woodard, Johannes R. Kratz, Greg J. Haro, Matthew A. Gubens, Collin M. Blakely, Kirk D. Jones, Michael J. Mann, David M. Jablons> ;Clinical Lung Cancer. 2021 Aug 20
59 citations
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA.
Masahiro Tsuboi, Walter Weder, C. Escriu, Collin M. Blakely, Jianxing He, Sanja Dacic, Yasushi Yatabe, Lingmin Zeng, Andrew Walding, Jamie E. Chaft> ;Future Oncology. 2021 Jul 19
10 citations
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
James Chih-Hsin Yang, Karen L. Reckamp, Young-Chul Kim, Silvia Novello, Egbert F. Smit, Jong Seok Lee, Wu Chou Su, Wallace Akerley, Collin M. Blakely, Harry J.M. Groen...> ;JTO Clinical and Research Reports. 2021 Feb 1
282 citations
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
Ashley Maynard, Caroline E. McCoach, Julia K Rotow, Lincoln Harris, Franziska Haderk, D. Lucas Kerr, Elizabeth A. Yu, Erin L. Schenk, Weilun Tan, Alexander Zee, Michel...> ;Cell. 2020 Sep 3
3 citations
Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial
Susan Y. Wu, Ann A. Lazar, Matthew A. Gubens, Collin M. Blakely, Alexander Gottschalk, David M. Jablons, Thierry Jahan, Victoria E. Wang, Taylor L Dunbar, Melisa L. Wo...> ;JAMA Network Open. 2020 Sep 1
14 citations
Impact of concurrent genomic alterations in epidermal growth factor receptor ( EGFR )-mutated lung cancer
Beatrice Gini, Nicholas J. Thomas, Collin M. Blakely> ;Journal of Thoracic Disease. 2020 Aug 4
6 citations
Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies.
Collin M. Blakely, Caroline E. McCoach> ;Clinical Cancer Research. 2020 Jul 15
813 citations
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;The Lancet. Oncology. 2020 Feb 1
60 citations
Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
Julia K Rotow, Philippe Gui, Wei Wu, Victoria M. Raymond, Richard B. Lanman, Frederic J. Kaye, Nir Peled, Ferran Fece de la Cruz, Brandon Nadres, Ryan B. Corcoran, Iwe...> ;Clinical Cancer Research. 2020 Jan 15
8 citations
Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.
Collin M. Blakely, Jonathan W. Riess> ;Expert Review of Anticancer Therapy. 2019 Dec 6
A New Pathway Emerges to Interpret Lung Cancer Genomic Alterations.
Collin M. Blakely> ;Clinical Cancer Research. 2019 Oct 14
7 citations
Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.
Julia K Rotow, Gavitt A. Woodard, Anatoly Urisman, Caroline E. McCoach, Trever G. Bivona, Brett M. Elicker, David M. Jablons, Collin M. Blakely> ;Clinical Lung Cancer. 2019 Mar 1
65 citations
Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
Patrick R Halliday, Collin M. Blakely, Trever G. Bivona> ;Current Oncology Reports. 2019 Feb 26
Join now to see all

Journal Articles

Aurora Kinase A Drives the Evolution of Resistance to Third-Generation EGFR Inhibitors in Lung Cancer
Victoria E Wang, Collin M Blakely, Trever G Bivona, Andrei Goga, Nature
Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping Mutation
Julia K Rotow, Trever G Bivona, Collin M Blakely, Clinical Lung Cancer

Authored Content

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping MutationNovember 2018

Press Mentions

Damon Runyon Cancer Research Foundation Awards $4.8 Million to Rising InvestigatorsJuly 15th, 2021
Deadly Lung Cancers Are Driven by Multiple Genetic ChangesNovember 6th, 2017
Deadly Lung Cancers Are Driven by Multiple Genetic ChangesNovember 6th, 2017
Join now to see all